🇺🇸 FDA
Patent

US 11813316

Lentiviral vector for treating hemoglobin disorders

granted A61KA61K38/42A61K48/005

Quick answer

US patent 11813316 (Lentiviral vector for treating hemoglobin disorders) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/42, A61K48/005